Quick Answer
AEON Biopharma, Inc. reported Net Income of -$39.22 million for fiscal year 2025.
AEON Biopharma, Inc. Net Income — Annual History
| Fiscal Year | Net Income | YoY Change |
|---|---|---|
| 2025 | -$39.22M | -193.4% |
| 2024 | $42.01M | +179.9% |
| 2022 | -$52.56M | -740.9% |
| 2021 | $8.20M | +228662.7% |
| 2020 | -$3.6K | — |
Quarterly Net Income
| Quarter Ending | Net Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$4.54M | +26.5% | +31.7% |
| June 30, 2025 | -$6.64M | -104.0% | -173.0% |
| March 31, 2025 | $9.10M | +107.7% | +247.4% |
| September 30, 2024 | -$6.17M | +97.9% | -103.8% |
| June 30, 2024 | $164.11M | +1167.1% | +239.1% |
| March 31, 2024 | -$118.02M | -569.1% | +60.4% |
| September 30, 2023 | -$297.71M | -2752.2% | -976.3% |
| July 31, 2023 | -$27.66M | — | -79.9% |
- AEON Biopharma, Inc. showed a decrease of -193.4% in Net Income compared to the prior fiscal year.
- Over the 2020–2025 period, AEON Biopharma, Inc.’s net income has declined by 1093043.8% (from -$3.6 thousand to -$39.22 million).
- The most recent figure is from AEON Biopharma, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 30, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: